Septic Shock

8
Pipeline Programs
8
Companies
14
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
1
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 13 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Octapharma
OctapharmaAustria - Vienna
2 programs
1
1
OctaplasLG®Phase 41 trial
OctaplasLGPhase 21 trial
Active Trials
NCT03092245Completed44Est. Apr 2019
NCT02875236Terminated5Est. Nov 2016
Grifols
GrifolsNEW YORK, NY
2 programs
1
Albutein® 200 g/L or Plasbumin® 20Phase 31 trial
Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic ShockN/A1 trial
Active Trials
NCT05094856CompletedEst. Mar 2023
NCT03869385TerminatedEst. Jun 2023
Precision BioSciences
1 program
1
Early VasopressinPhase 31 trial
Active Trials
NCT06464510Recruiting2,800Est. Sep 2027
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
3 programs
2
1
selepressinPhase 2/31 trial
FE 202158Phase 21 trial
FE 202158 1.25Phase 21 trial
Active Trials
NCT01612676Completed31Est. Nov 2013
NCT01000649Completed53Est. Sep 2011
NCT02508649Terminated868Est. Feb 2018
Adrenomed
AdrenomedGermany - Hennigsdorf
1 program
1
AdrecizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03085758Completed301Est. Dec 2019
CytoSorbents
CytoSorbentsPRINCETON, NJ
4 programs
CytoSorbN/A1 trial
CytoSorb-TherapyN/A1 trial
Cytokine AdsorptionN/A1 trial
Cytosorb® 300 mlN/A1 trial
Active Trials
NCT05146336Recruiting3,000Est. Sep 2032
NCT04013269Unknown32Est. Dec 2023
NCT04910893Completed48Est. Dec 2018
+1 more trials
ExThera Medical
ExThera MedicalCA - Martinez
1 program
Seraph-100 + State of the Art CareN/A1 trial
Active Trials
NCT05011656Active Not Recruiting15Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
OctapharmaOctaplasLG®
Precision BioSciencesEarly Vasopressin
GrifolsAlbutein® 200 g/L or Plasbumin® 20
Ferring Pharmaceuticalsselepressin
AdrenomedAdrecizumab
OctapharmaOctaplasLG
Ferring PharmaceuticalsFE 202158
Ferring PharmaceuticalsFE 202158 1.25
ExThera MedicalSeraph-100 + State of the Art Care
CytoSorbentsCytoSorb
GrifolsEffects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Shock
CytoSorbentsCytosorb® 300 ml
CytoSorbentsCytoSorb-Therapy
CytoSorbentsCytokine Adsorption

Clinical Trials (14)

Total enrollment: 7,457 patients across 14 trials

NCT02875236OctapharmaOctaplasLG®

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)

Start: Sep 2016Est. completion: Nov 20165 patients
Phase 4Terminated
NCT06464510Precision BioSciencesEarly Vasopressin

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Start: Nov 2024Est. completion: Sep 20272,800 patients
Phase 3Recruiting
NCT03869385GrifolsAlbutein® 200 g/L or Plasbumin® 20

Albumin Replacement Therapy in Septic Shock

Start: Oct 2019Est. completion: Jun 2023
Phase 3Terminated
NCT02508649Ferring Pharmaceuticalsselepressin

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Start: Jul 2015Est. completion: Feb 2018868 patients
Phase 2/3Terminated
NCT03085758AdrenomedAdrecizumab

Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB

Start: Dec 2017Est. completion: Dec 2019301 patients
Phase 2Completed
NCT03092245OctapharmaOctaplasLG

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial

Start: Apr 2017Est. completion: Apr 201944 patients
Phase 2Completed
NCT01612676Ferring PharmaceuticalsFE 202158

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Start: Jun 2012Est. completion: Nov 201331 patients
Phase 2Completed
NCT01000649Ferring PharmaceuticalsFE 202158 1.25

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Start: Nov 2009Est. completion: Sep 201153 patients
Phase 2Completed
NCT05011656ExThera MedicalSeraph-100 + State of the Art Care

Blood Purification for the Treatment of Pathogen Associated Shock

Start: Apr 2024Est. completion: Sep 202515 patients
N/AActive Not Recruiting
NCT05146336CytoSorbentsCytoSorb

CytOSorb TreatMent Of Critically Ill PatientS Registry

Start: Jun 2022Est. completion: Sep 20323,000 patients
N/ARecruiting
NCT05094856GrifolsEffects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Shock

Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Shock

Start: Feb 2022Est. completion: Mar 2023
N/ACompleted
NCT04963920CytoSorbentsCytosorb® 300 ml

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

Start: Jan 2022Est. completion: May 2027260 patients
N/ASuspended
NCT04013269CytoSorbentsCytoSorb-Therapy

Adjuvant Therapy With CytoSorb in Refractory Septic Shock

Start: Jan 2020Est. completion: Dec 202332 patients
N/AUnknown
NCT04910893CytoSorbentsCytokine Adsorption

Cytokine Adsorption in Severe, Refractory Septic Shock

Start: Nov 2014Est. completion: Dec 201848 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 7,457 patients
8 companies competing in this space